An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Inclusion Criteria:

1. Documented diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening, including ileal, colonic, or ileo-colonic disease distribution
2. Must have had an inadequate response, loss of response, or intolerance to 1 or more of the standard treatments
3. Must have active moderate to severe CD
4. Men and women must agree to follow specific methods of contraception, if applicable

Exclusion Criteria:

1. Severe or fulminant colitis that is likely to require surgery or hospitalization
2. Presence of a diagnosis of alternative forms of colitis (infectious, inflammatory including ulcerative colitis, malignant, toxic, indeterminate, etc.) other than Crohn's Disease
3. Previous exposure to BMS-986165 in any study
4. Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, psychiatric, or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the participant

Other protocol-defined inclusion/exclusion criteria apply